Pennington, NJ, United States of America

Eric M Gordon

This inventor holds 100 USPTO granted patents and 4 published patent applications, plus 18 CIPO patents and 3 EPO patents, primarily in Beta-Lactam Inhibitors (CPC class 548533). Top assignees: E. R. Squibb Sons, Inc., Arixa Pharmaceuticals, Inc., Pharmacia & Upjohn Company. Active years: 1978-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eric M Gordon. Retrieved from https://idiyas.com/inventor/eric-m-gordon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 100 (Patent Applications = 4)

% Patents Active = 98.0

CIPO Patents = 18 (Patent Applications = 24)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 2.1

ph-index = 16

Forward Citations = 1,035(Granted Patents)

Forward Citations (Not Self Cited) = 959(Dec 10, 2025)

Inventors with similar research interests:

Location History:

West Trenton, NJ (US) (1978 - 1983)
Pennington, NJ (US) (1979 - 2000)
Palo alto, CA (US) (1994 - 2023)

Company Filing History:

85 out of 1,624

E. R. Squibb Sons, Inc.

patents

8 out of 9

Arixa Pharmaceuticals, Inc.

patents

3 out of 523

Pharmacia & Upjohn Company

Bristol-Myers Squibb Compnay

Skyline Antiinfectives, Inc.

patent

Years Active: 1978-2023

Loading Chart...

Areas of Expertise:

Aztreonam Derivatives

Beta-Lactamase Inhibitors

Oxazolidinone Libraries

HMG-CoA Reductase Inhibitors

Protease Inhibitors

Synthetic Library

Mevinic Acid Derivatives

Combinatorial Libraries

Hydroxamic Acids

Encoded Libraries

Aminediol Inhibitors

Neoplastic Transformation

100 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11565999 - Methods of synthesizing aztreonam derivatives (2023-01-31),

2. 11180500 - Derivatives of relebactam and uses thereof (2021-11-23),

3. 10815228 - Aztreonam derivatives and uses thereof (2020-10-27),

4. 10722521 - Beta-lactamase inhibitors and uses thereof (2020-07-28),

5. 10500211 - Beta-lactamase inhibitors and uses thereof (2019-12-10),

6. 10280161 - Aztreonam derivatives and uses thereof (2019-05-07),

7. 10093666 - Deuterated O-sulfated beta lactam hydroxamic acids and deuterated N-sulfated beta lactams (2018-10-09),

8. 10085999 - Beta-lactamase inhibitors and uses thereof (2018-10-02),

9. 10047077 - Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams (2018-08-14),

10. 6562844 - Oxazolidinone combinatorial libraries, compositions and methods of preparation (2003-05-13),

11. 6531470 - Oxazolidinone combinatorial libraries, compositions and methods of preparation (2003-03-11),

12. 6368874 - Methods for hard-tagging an encoded synthetic library (2002-04-09),

13. 6239152 - Oxazolidinone combinatorial libraries, compositions and methods of preparation (2001-05-29),

14. 6087349 - Method for blocking neoplastic transformation of cells induced by ras (2000-07-11),

15. 5846839 - Methods for hard-tagging an encoded synthetic library (1998-12-08),

Title: The Innovative Contributions of Eric M. Gordon

Introduction: Eric M. Gordon is a distinguished inventor based in Pennington, NJ, renowned for his extensive contributions to the field of pharmacology, boasting a remarkable portfolio of 100 patents. His innovative work focuses on developing new therapeutic methods and pharmaceutical compositions, showcasing a deep commitment to medical advancements.

Latest Patents: Among his latest patents are groundbreaking methods of synthesizing aztreonam derivatives. These comprise not only novel therapeutic methods for administering these derivatives but also effective synthesis techniques for creating orally bioavailable aztreonam. Another significant advancement is the patent covering derivatives of relebactam, which highlights their therapeutic application, especially in combination with β-lactam antibiotics. The focus on oral administration for these derivatives underscores his dedication to enhancing patient accessibility to essential medications.

Career Highlights: Eric M. Gordon has built a notable career in research and development, working with reputable companies such as E.R. Squibb & Sons, Inc. and Arixa Pharmaceuticals, Inc. His work at these firms has significantly impacted the pharmaceutical landscape, particularly in antibiotic development.

Collaborations: Throughout his career, Eric has collaborated with esteemed colleagues, including Ravi K. Varma and Harold N. Weller, III. These partnerships have fostered a dynamic exchange of ideas, leading to innovative solutions in drug formulation and therapeutic applications.

Conclusion: Eric M. Gordon's impressive body of work and commitment to innovation in pharmaceuticals exemplify the crucial role of patenting in the advancement of medical science. His patents, particularly in synthesizing aztreonam and relebactam derivatives, highlight his impact on future therapeutic pathways, ensuring that new medications will continue to be developed for better patient care.

Profile summary based on public USPTO records.